Last reviewed · How we verify
NCT05359263: DECODE-CKD
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD
Recruiting now
Phase 2
Last updated 10 February 2025
What this trial tests
Phase 2 trial testing Dapagliflozin 10 mg in Chronic Kidney Diseases in 222 participants. Currently enrolling.
Timeline
8 June 2022
Primary endpoint
18 February 2025
18 February 2025
18 February 2025
Quick facts
| Lead sponsor | Tor Biering-Sørensen |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 222 |
| Start date | 8 June 2022 |
| Primary completion | 18 February 2025 |
| Estimated completion | 18 February 2025 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Dapagliflozin 10 mg — full drug profile →
- Placebo
Conditions studied
- Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
Sponsor
Tor Biering-Sørensen — full company profile →
Who can join
18 and older, any sex, with Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate the effects of dapagliflozin on echocardiographic measures of cardiac structure and function in patients with chronic kidney disease.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Lipocalin 2-not only a biomarker: a study of current literature and systematic findings of ongoing clinical trials.
Asaf S, Maqsood F, Jalil J, Sarfraz Z, et al · · 2023 · cited 38× · PMID 36529828 · DOI 10.1007/s12026-022-09352-2 -
Klotho's impact on diabetic nephropathy and its emerging connection to diabetic retinopathy.
Tang A, Zhang Y, Wu L, Lin Y, et al · · 2023 · cited 35× · PMID 37143722 · DOI 10.3389/fendo.2023.1180169 -
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial.
Bartholdy KV, Johansen ND, Landler N, Skaarup KG, et al · · 2023 · cited 5× · PMID 36649484 · DOI 10.34067/kid.0006982022 -
Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease.
Bartholdy KV, Johansen ND, Skaarup KG, Modin D, et al · · 2025 · cited 3× · PMID 41147829 · DOI 10.1056/evidoa2500158 -
Dapagliflozin and Cardiac Reverse Remodeling: New Insights in the Mechanistic Puzzle of SGLT2 Inhibitors.
Chatur S, Churchill TW. · · 2025 · cited 2× · PMID 39778606 · DOI 10.1016/j.echo.2025.01.002 -
Cardiovascular pharmacotherapy in 2025.
Tamargo J, Agewall S, Ambrosio G, Borghi C, et al · · 2026 · PMID 41935384 · DOI 10.1093/ehjcvp/pvag016
Verify or expand the search:
- PubMed search for NCT05359263
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dapagliflozin 10 mg
Trials testing the same drug.
- NCT07280585 — STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease · Phase 3 · recruiting
- NCT07083401 — A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and · Phase 1 · recruiting
- NCT07083388 — A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and · Phase 1 · recruiting
- NCT06982079 — Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease · Phase 3 · recruiting
- NCT06711185 — Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy · Phase 3 · recruiting
Other recruiting trials for Chronic Kidney Diseases
Currently open trials in the same condition.
- NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus · Phase 2 · recruiting
- NCT07358572 — Eye-Brain-Kidney in CKD · recruiting
- NCT06463483 — Automated Insulin Delivery in Adults With Advanced Kidney Disease · NA · recruiting
- NCT06927024 — Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD) · NA · recruiting
- NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension · NA · recruiting
Other Tor Biering-Sørensen trials
Trials by the same sponsor.
- NCT06952140 — Hemodynamic Effects of Ketone Esters in Patients With Sepsis Induced Cardiomyopathy · NA · not yet recruiting
- NCT06694727 — A Danish Pragmatic Randomized Trial of Nutritional Supplements in Heart Failure · Phase 3 · recruiting
- NCT06506812 — Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vacc · Phase 4 · completed
- NCT06685237 — Copenhagen Heart Failure With Preserved Ejection Fraction · recruiting
- NCT06856772 — Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05359263 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tor Biering-Sørensen
- Last refreshed: 10 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05359263.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing